Unknown

Dataset Information

0

Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.


ABSTRACT: The development of resistance and the activation of bypass pathway signalling represents a major problem for the clinical application of protein kinase inhibitors. While investigating the effect of either a c-Rel deletion or RelAT505A phosphosite knockin on the Eµ-Myc mouse model of B-cell lymphoma, we discovered that both NF-κB subunit mutations resulted in CHK1 inhibitor resistance, arising from either loss or alteration of CHK1 activity, respectively. However, since Eµ-Myc lymphomas depend on CHK1 activity to cope with high levels of DNA replication stress and consequent genomic instability, it was not clear how these mutant NF-κB subunit lymphomas were able to survive. To understand these survival mechanisms and to identify potential compensatory bypass signalling pathways in these lymphomas, we applied a multi-omics strategy. With c-Rel-/- Eµ-Myc lymphomas we observed high levels of Phosphatidyl-inositol 3-kinase (PI3K) and AKT pathway activation. Moreover, treatment with the PI3K inhibitor Pictilisib (GDC-0941) selectively inhibited the growth of reimplanted c-Rel-/- and RelAT505A, but not wild type (WT) Eµ-Myc lymphomas. We also observed up-regulation of a RHO/RAC pathway gene expression signature in both Eµ-Myc NF-κB subunit mutation models. Further investigation demonstrated activation of the RHO/RAC effector p21-activated kinase (PAK) 2. Here, the PAK inhibitor, PF-3758309 successfully overcame resistance of RelAT505A but not WT lymphomas. These findings demonstrate that up-regulation of multiple bypass pathways occurs in CHK1 inhibitor resistant Eµ-Myc lymphomas. Consequently, drugs targeting these pathways could potentially be used as either second line or combinatorial therapies to aid the successful clinical application of CHK1 inhibitors.

SUBMITTER: Hunter JE 

PROVIDER: S-EPMC9704644 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.

Hunter Jill E JE   Campbell Amy E AE   Kerridge Scott S   Fraser Callum C   Hannaway Nicola L NL   Luli Saimir S   Ivanova Iglika I   Brownridge Philip J PJ   Coxhead Jonathan J   Taylor Leigh L   Leary Peter P   Hasoon Megan S R MSR   Eyers Claire E CE   Perkins Neil D ND  

The Biochemical journal 20221001 19


The development of resistance and the activation of bypass pathway signalling represents a major problem for the clinical application of protein kinase inhibitors. While investigating the effect of either a c-Rel deletion or RelAT505A phosphosite knockin on the Eµ-Myc mouse model of B-cell lymphoma, we discovered that both NF-κB subunit mutations resulted in CHK1 inhibitor resistance, arising from either loss or alteration of CHK1 activity, respectively. However, since Eµ-Myc lymphomas depend on  ...[more]

Similar Datasets

| S-EPMC5864240 | biostudies-literature
| S-EPMC4823038 | biostudies-literature
| S-EPMC5029604 | biostudies-literature
| S-EPMC11745823 | biostudies-literature
| S-EPMC8760370 | biostudies-literature
2014-09-10 | GSE40759 | GEO
2014-08-13 | GSE60342 | GEO
2014-09-10 | E-GEOD-40759 | biostudies-arrayexpress
| S-EPMC6719623 | biostudies-literature
| S-EPMC3784531 | biostudies-literature